---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-016726"
form_type: "8-K"
ticker: "ICU"
cik: "0001831868"
company_name: "SeaStar Medical Holding Corp"
filed_at: "2026-05-13T20:12:25+00:00"
generated_at: "2026-05-13T22:00:35.341061+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# SeaStar Medical Q1 revenue $0.5M, up 69% YoY; net loss $3.5M

## Summary
- Net revenue of $0.5M from QUELIMMUNE sales, vs $0.3M in Q1 2025.
- Net loss $3.5M ($0.90/share) vs $3.8M ($4.38/share) a year ago.
- Cash $9.3M at March 31, down from $12.0M at Dec 31, 2025.
- NEUTRALIZE-AKI trial enrolled 198 of 339 patients; PMA submission efforts initiated.
- Added 7 children’s hospitals, now 17 total, targeting 15 more in 2026.

## SEC filing metadata
- accession: 0001437749-26-016726
- form_type: 8-K
- ticker: ICU
- cik: 0001831868
- company_name: SeaStar Medical Holding Corp
- filed_at: 2026-05-13T20:12:25+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1831868/000143774926016726/0001437749-26-016726-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1831868/000143774926016726/icu20260408_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-016726
- JSON: https://secwatch.observer/filing/0001437749-26-016726.json
- Plain text: https://secwatch.observer/filing/0001437749-26-016726.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.